| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Zingibroside R1 targets multiple pathways involved in cancer progression and viral infection. Its primary targets include HIV, against which it shows anti-HIV-1 activity. It exhibits anti-tumor effects by being cytotoxic to melanoma cells and shows anti-angiogenic activity by inhibiting tube formation in HUVECs. It also inhibits 2-deoxy-D-glucose (2-DG) uptake, suggesting an effect on glucose metabolism in cancer cells. These diverse activities make it a compound of interest for cancer and antiviral research.
|
|---|---|
| ln Vitro |
In vitro, Zingibroside R1 is cytotoxic to B16/F10 murine melanoma cells with an IC50 of 24.52 µg/ml. It inhibits tube formation by human umbilical vein endothelial cells (HUVECs) when used at a concentration of 40 µg/ml, indicating anti-angiogenic activity. It also inhibits the 2-deoxy-D-glucose (2-DG) uptake by EAT cells with an IC50 of 91.3 μM, suggesting an effect on glucose metabolism. These in vitro activities support its potential as an anti-cancer and anti-angiogenic agent.
|
| ln Vivo |
In vivo activity data for Zingibroside R1 is limited in publicly available literature. As a compound with potent anti-tumor, anti-angiogenic, and anti-HIV-1 activity in vitro, it is hypothesized to exhibit similar effects in animal models. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free enzyme assays, the anti-HIV-1 activity of Zingibroside R1 can be studied using HIV-1 reverse transcriptase or protease inhibition assays. The compound is incubated with the purified enzyme and its substrate, and the inhibition of enzyme activity is measured. The IC50 for enzyme inhibition can be calculated. Its anti-angiogenic activity can be assessed in cell-free systems by measuring its effect on the activity of matrix metalloproteinases (MMPs) or other angiogenic factors.
|
| Cell Assay |
For in vitro cellular assays, the anti-tumor activity of Zingibroside R1 is typically assessed in cancer cell lines, such as B16/F10 murine melanoma cells. Cells are seeded in multi-well plates and treated with varying concentrations of the compound for a defined period. Cell viability is measured using MTT, MTS, or SRB assays, and the IC50 value is calculated. Its anti-angiogenic activity is assessed using a tube formation assay with HUVECs. The effect on glucose metabolism can be studied by measuring 2-deoxy-D-glucose (2-DG) uptake.
|
| Animal Protocol |
For in vivo studies, Zingibroside R1 could be administered orally or intraperitoneally in rodent models of cancer or viral infection. In a xenograft model, its anti-tumor efficacy would be assessed by measuring tumor volume over time. In a model of angiogenesis, its anti-angiogenic effect could be assessed by measuring the formation of new blood vessels in a Matrigel plug assay. In an HIV-1 model, its antiviral efficacy could be assessed by measuring viral load.
|
| ADME/Pharmacokinetics |
Zingibroside R1 has a molecular formula of C42H66O14 and a molecular weight of 795.0 g/mol. Its CAS number is 80930-74-1. It is a triterpenoid saponin and is typically supplied as a white crystalline powder. It is soluble in DMSO and ethanol. For in vitro studies, stock solutions are prepared in DMSO. For in vivo administration, it can be formulated in suitable vehicles. Storage is recommended at -20°C, protected from light. Its purity is typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural triterpenoid saponin, its safety profile would need to be established through standard toxicological studies. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that the observed effects are not due to a general reduction in cell viability.
|
| References |
|
| Additional Infomation |
According to reports, ginseng, long-leaf camellia, and multiflora camellia contain gingerol R1, and there is relevant data.
Zingibroside R1 is a research-grade compound and is not approved for any therapeutic use. It serves primarily as a valuable pharmacological tool for studying cancer, angiogenesis, and viral infection. Its mechanism of action involves cytotoxicity against cancer cells, inhibition of angiogenesis, and anti-HIV-1 activity. These diverse activities make it a compound of interest for drug discovery. No clinical trials have been reported. |
| Molecular Formula |
C42H66O14
|
|---|---|
| Molecular Weight |
794.965054988861
|
| Exact Mass |
794.445
|
| CAS # |
80930-74-1
|
| PubChem CID |
10395524
|
| Appearance |
White to off-white solid powder
|
| Density |
1.37±0.1 g/cm3
|
| LogP |
4.5
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
56
|
| Complexity |
1560
|
| Defined Atom Stereocenter Count |
18
|
| SMILES |
C[C@]12[C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@@H]5O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]5O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC[C@@]4([C@H]3CC=C1[C@@H]1CC(C)(C)CC[C@@]1(CC2)C(=O)O)C)C
|
| InChi Key |
WJQOMUVKRDJBGZ-COUNGWPASA-N
|
| InChi Code |
InChI=1S/C42H66O14/c1-37(2)14-16-42(36(51)52)17-15-40(6)20(21(42)18-37)8-9-24-39(5)12-11-25(38(3,4)23(39)10-13-41(24,40)7)54-35-32(29(47)28(46)31(55-35)33(49)50)56-34-30(48)27(45)26(44)22(19-43)53-34/h8,21-32,34-35,43-48H,9-19H2,1-7H3,(H,49,50)(H,51,52)/t21-,22+,23-,24+,25-,26+,27-,28-,29-,30+,31-,32+,34-,35+,39-,40+,41+,42-/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(3S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4-dihydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~125.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2579 mL | 6.2895 mL | 12.5791 mL | |
| 5 mM | 0.2516 mL | 1.2579 mL | 2.5158 mL | |
| 10 mM | 0.1258 mL | 0.6290 mL | 1.2579 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
